Last Updated on: 5th March 2024, 02:31 pm
Applied Biopharm Consulting Ltd is the proud recipient of a grant from the Local Enterprise Office Cork North and West, designated for a feasibility study focusing on the application of artificial intelligence and sophisticated computational methodologies for the engineering of viral capsids and various molecules within an office setting. The grant allocation extends to acquiring software licenses and enhancing computing infrastructure.
The company is set to enhance the development trajectory of biomolecules, with a particular focus on engineered adeno-associated virus (AAV) vectors, employing molecular screening strategies. This effort is poised to heighten the effectiveness of gene therapy delivery mechanisms to targeted cells, marking a significant stride in the treatment of intricate health issues where traditional medical approaches may be inadequate.
At the heart of Applied Biopharm’s forward-thinking strategy lies the implementation of computer-based analytical tools capable of delving into extensive datasets of protein structures. Such comprehensive analysis paves the way for predicting protein behaviours, such as folding and interactions, thereby facilitating the generation of innovative gene therapy solutions that boast improved tissue specificity, delivery, and potency. The technology’s versatile nature also opens avenues for the development of novel therapeutic approaches beyond the scope of AAV vectors.
Dr. Anthony Newcombe, Managing Director at Applied Biopharm Consulting Ltd., remarked, “Our goal is to develop applications to advance biopharmaceutical development by combining artificial intelligence, computational tools and molecular simulations to engineer AAV vectors and other biomolecules with improved precision.”
Kevin Curran, Head of Enterprise from the Local Enterprise Office Cork North and West, conveyed, “We are delighted to provide a feasibility study grant to Applied Biopharm Consulting Ltd and we look forward to seeing the positive impact of their research.”
The provision of this grant underlines Applied Biopharm’s unwavering commitment to pioneering innovative practices in the biopharmaceutical realm. The company’s steadfast focus on consultancy services continues to play a pivotal role in supporting clients towards realising their manufacturing, compliance, and market introduction objectives for life-saving products.
